Volume 3 Supplement 1

2006 International Meeting of The Institute of Human Virology

Open Access

Non-neutralizing antibodies and vaccine-induced protection

  • Thorsten Demberg1,
  • Ruth H Florese1,
  • V Raul Gomez-Roman1,
  • Kay Larsen2,
  • Koen KA Van Rompay3,
  • Marta L Marthas3,
  • David Venzon4,
  • VS Kalyanaraman5,
  • Ranajit Pal5,
  • Susan W Barnett6,
  • Aurelio Cafaro7,
  • Barbara Ensoli7 and
  • Marjiorie Robert-Guroff1
Retrovirology20063(Suppl 1):S26

DOI: 10.1186/1742-4690-3-S1-S26

Published: 21 December 2006

Neutralizing antibody is critical for sterilizing immunity, but recent data suggest binding antibodies may contribute to protection. A replicating Ad-HIVenv prime/Env protein boost regimen induced potent antibodies with broad antibody-dependent cellular cytotoxic activity (ADCC) across HIV clades. A multigenic Ad-SIV prime/Env subunit boost regimen elicited strong protection in rhesus macaques against SIVmac251. Significant reduction in acute viremia was correlated with non-neutralizing, ADCC-mediating anti-Env antibodies. Further, compared to multigenic vaccines, an Ad-HIVtat+Ad-HIVenv prime/Tat and Env protein boost regimen elicited significantly enhanced protection against SHIV89.6P associated with Tat and Env binding antibodies. Passive transfer of ADCC-mediating IgG has not protected neonatal macaques against oral SIV challenge. But a high challenge dose, limited IgG, and poorly functional or insufficient neonatal NK effector cells may have precluded protection. In future, other challenge routes will be studied in juvenile macaques using more ADCC-mediating IgG.

Authors’ Affiliations

(1)
Vaccine Branch, NCI, NIH
(2)
Washington National Primate Research Center
(3)
California National Primate Research Center
(4)
Biostatistics and Data Management Section, NCI, NIH
(5)
Advanced BioScience Laboratories, Inc.
(6)
Novartis Vaccines
(7)
National AIDS Center, Istituto Superiore di Sanita

Copyright

© Demberg et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.

Advertisement